Literature DB >> 27552154

MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.

Giulia Calenda1, Guillermo Villegas, Patrick Barnable, Claudia Litterst, Keith Levendosky, Agegnehu Gettie, Michael L Cooney, James Blanchard, José A Fernández-Romero, Thomas M Zydowsky, Natalia Teleshova.   

Abstract

The Population Council's microbicide gel MZC (also known as PC-1005) containing MIV-150 and zinc acetate dihydrate (ZA) in carrageenan (CG) has shown promise as a broad-spectrum microbicide against HIV, herpes simplex virus (HSV), and human papillomavirus. Previous data show antiviral activity against these viruses in cell-based assays, prevention of vaginal and rectal simian-human immunodeficiency virus reverse transcriptase (SHIV-RT) infection, and reduction of vaginal HSV shedding in rhesus macaques and also excellent antiviral activity against HSV and human papillomavirus in murine models. Recently, we demonstrated that MZC is safe and effective against SHIV-RT in macaque vaginal explants. Here we established models of ex vivo SHIV-RT/HSV-2 coinfection of vaginal mucosa and SHIV-RT infection of rectal mucosa in macaques (challenge of rectal mucosa with HSV-2 did not result in reproducible tissue infection), evaluated antiviral activity of MZC, and compared quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay readouts for monitoring SHIV-RT infection. MZC (at nontoxic dilutions) significantly inhibited SHIV-RT in vaginal and rectal mucosas and HSV-2 in vaginal mucosa when present during viral challenge. Analysis of SHIV-RT infection and MZC activity by 1-step simian immunodeficiency virus gag quantitative RT-PCR and p27 enzyme-linked immunosorbent assay demonstrated similar virus growth dynamics and MZC activity by both methods and higher sensitivity of quantitative RT-PCR. Our data provide more evidence that MZC is a promising dual compartment multipurpose prevention technology candidate.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27552154      PMCID: PMC5303173          DOI: 10.1097/QAI.0000000000001167

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  62 in total

1.  MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.

Authors:  Patrick Barnable; Giulia Calenda; Thierry Bonnaire; Radhika Menon; Keith Levendosky; Agegnehu Gettie; James Blanchard; Michael L Cooney; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.

Authors:  Nicola Richardson-Harman; Christine Mauck; Ian McGowan; Peter Anton
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-20       Impact factor: 2.205

3.  Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults.

Authors:  Karen E Mark; Anna Wald; Amalia S Magaret; Stacy Selke; Steven Kuntz; Meei-Li Huang; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection.

Authors:  Elena Martinelli; Filippo Veglia; Diana Goode; Natalia Guerra-Perez; Meropi Aravantinou; James Arthos; Michael Piatak; Jeffrey D Lifson; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

5.  Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.

Authors:  Dianne J Marais; Jo-Ann S Passmore; Lynette Denny; Candice Sampson; Bruce R Allan; Anna-Lise Williamson
Journal:  J Med Virol       Date:  2008-06       Impact factor: 2.327

6.  Caspase 9 is essential for herpes simplex virus type 2-induced apoptosis in T cells.

Authors:  Michael J Vanden Oever; Jin-Young Han
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

7.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

8.  An ex vivo Model of HIV-1 Infection in Human Lymphoid Tissue and Cervico-vaginal Tissue.

Authors:  Andrea Introini; Christophe Vanpouille; Jean Charles Grivel; Leonid Margolis
Journal:  Bio Protoc       Date:  2014

9.  An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.

Authors:  Jessica Kenney; Meropi Aravantinou; Rachel Singer; Mayla Hsu; Aixa Rodriguez; Larisa Kizima; Ciby J Abraham; Radhika Menon; Samantha Seidor; Anne Chudolij; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

10.  HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target.

Authors:  Elena Martinelli; Hugo Tharinger; Ines Frank; James Arthos; Michael Piatak; Jeffrey D Lifson; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS Pathog       Date:  2011-06-30       Impact factor: 6.823

View more
  8 in total

1.  MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1.

Authors:  Olga Mizenina; Mayla Hsu; Ninochka Jean-Pierre; Meropi Aravantinou; Keith Levendosky; Gabriela Paglini; Thomas M Zydowsky; Melissa Robbiani; José A Fernández-Romero
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 5.671

Review 2.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

3.  Carrageenan-Based Acyclovir Mucoadhesive Vaginal Tablets for Prevention of Genital Herpes.

Authors:  Edisson-Mauricio Pacheco-Quito; Roberto Ruiz-Caro; Juan Rubio; Aitana Tamayo; María-Dolores Veiga
Journal:  Mar Drugs       Date:  2020-05-11       Impact factor: 5.118

4.  Superinfection and cell regeneration can lead to chronic viral coinfections.

Authors:  Lubna Pinky; Gilberto González-Parra; Hana M Dobrovolny
Journal:  J Theor Biol       Date:  2019-01-11       Impact factor: 2.691

5.  Correlation between detergent activity and anti-herpes simplex virus-2 activity of commercially available vaginal gels.

Authors:  Andrea Szöllősi; Tímea Raffai; Anita Bogdanov; Valéria Endrész; László Párducz; Ferenc Somogyvári; László Janovák; Katalin Burián; Dezső P Virok
Journal:  BMC Res Notes       Date:  2020-01-31

Review 6.  Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.

Authors:  Fernando Notario-Pérez; Roberto Ruiz-Caro; María-Dolores Veiga-Ochoa
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

7.  Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.

Authors:  Nina Derby; Manjari Lal; Meropi Aravantinou; Larisa Kizima; Patrick Barnable; Aixa Rodriguez; Manshun Lai; Asa Wesenberg; Shweta Ugaonkar; Keith Levendosky; Olga Mizenina; Kyle Kleinbeck; Jeffrey D Lifson; M Melissa Peet; Zachary Lloyd; Michael Benson; Walid Heneine; Barry R O'Keefe; Melissa Robbiani; Elena Martinelli; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Natalia Teleshova; José A Fernández-Romero; Thomas M Zydowsky
Journal:  Nat Commun       Date:  2018-09-24       Impact factor: 14.919

Review 8.  The current state of animal models and genomic approaches towards identifying and validating molecular determinants of Mycobacterium tuberculosis infection and tuberculosis disease.

Authors:  Allison N Bucsan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Pathog Dis       Date:  2019-06-01       Impact factor: 3.166

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.